Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience | Zendy

Fredrik Sund | Zendy; Gunnar Tufveson | Zendy; Bernd Döhler | Zendy; Gerhard Opelz | Zendy; BrittMarie Eriksson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience

Author(s) -

Fredrik Sund,

Gunnar Tufveson,

Bernd Döhler,

Gerhard Opelz,

BrittMarie Eriksson

Publication year - 2012

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfs531

Subject(s) - medicine , renal transplant , adverse effect , transplantation , gastroenterology

Cytomegalovirus (CMV) remains an important pathogen in transplant patients, and valacyclovir (VACV) prophylaxis 8 g/day has been used in high-risk CMV-seromismatched [D+/R-] renal transplant patients to decrease CMV disease. Neurotoxic adverse effects have limited its use, and the aim of the present study was to retrospectively evaluate low-dose VACV prophylaxis, 3 g/day for 90 days after transplantation, in 102 D+/R- renal transplant patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research